Clinical Trial Update: Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Puxitatug Samrotecan (AZD8205) as monotherapy versus chemotherapy in B7-H4-selected endometrial cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Puxitatug Samrotecan (AZD8205)

Snippet

Sponsor: AstraZeneca | Conditions: Endometrial Cancer, Malignant Solid Tumour | Phase 3 | Status: RECRUITING